Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Byrna Technologies Inc (BYRN) Price & Performance

BioNTech SE - ADRTrade
Byrna Technologies IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Byrna Technologies Inc — how do they compare? BioNTech SE - ADR trades at $92.23 (market cap $23.31B), while Byrna Technologies Inc trades at $4.68 (market cap $109.84M). The key difference: BioNTech SE - ADR is far larger — about 212.2× Byrna Technologies Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.

BNTXBYRN
Market Cap
$23.31B$109.84M
Sector
HealthTechnology
52-Week High
$119.34$27.63
52-Week Low
$83.89$3.18
Enterprise Value
$6.60B$101.44M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.

Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.

Byrna Technologies Inc

BYRN trades at $4.45, up 2.06% today, but faces bearish technical signals and recent earnings challenges. The company reported a Q2 2026 loss of $0.44 per share, missing estimates, with revenue declining 42.5% year-over-year. Despite a 71.4% analyst buy rating, negative net income margin and cash flow concerns highlight operational headwinds. Recent management appointments aim to revitalize marketing and retail growth.

Outlook remains cautious due to weak sales trends and profitability issues, though strategic hires and acquisitions could support a turnaround. Key risks include sustained revenue declines and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Byrna Technologies Inc

Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.

Read more on BYRN